Euroapi Company Header Euroapi Company Header

X
[{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isu Abxis, Ranked First for Two Consecutive Years in the Algerian Gaucher Disease Treatment Bidding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isu Abxis Expects 100% Exclusive Treatment for Gaucher Disease in Algeria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Imiglucerase

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.

            Lead Product(s): Imiglucerase

            Therapeutic Area: Genetic Disease Product Name: Abcertin

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 22, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.

            Lead Product(s): Imiglucerase

            Therapeutic Area: Genetic Disease Product Name: Abcertin

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 12, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY